Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors.

Objectives: Previous research has suggested that endocrine therapy is associated with cognitive limitations in breast cancer survivors (BCS); this study examined the relationship in employed BCS, an average of three years post-primary treatment.

Methods: 77 BCS with past or current exposure to tamoxifen or aromatase inhibitors and 56 BCS with no history of endocrine therapy completed self-report measures of cognitive function, anxiety, depression, and fatigue as well as an online neurocognitive battery.

Results: Exposure to endocrine therapy was not related to scores on the objective measures, but moderately related to perceived attentional problems at work (β = -0.